1414 Antitumor effect of HER2-hICD vaccine combining with HER2 ADC depending on T cell existence in a mouse model: pooled analysis

1414 Antitumor effect of HER2-hICD vaccine combining with HER2 ADC depending on T cell existence in a mouse model: pooled analysis

Bibliographic Details
Main Authors:	Hye-Ran Kim, Eunkyo Joung, Jinback Lim, Hyo-Hyun Park, Hun Jung, Jinho Kang, Chul-Woong Chung, Soyeon Lim, Yun-Hee Park, Jin Kyeong Choi, Jee Hyun Choi, Seong-Yong Jang, Min-Ah Kim, Myeong-Kyu Park
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

897 AST-301, a pDNA-based cancer vaccine encoding HER2-ICD, enhances anti-tumor effect of HER2-ADC in a HER2-expressed gastric cancer xenograft model
by: Eunkyo Joung, et al.
Published: (2023-11-01)

776 The anti-tumor activity of HER-2/neu ICD therapeutic cancer vaccine (AST-301, pNGVL3-hICD) in Her2-expressed gastric cancer xenograft model
by: Gyeong Seok Jo, et al.
Published: (2021-11-01)

1421 Th1-specific epitope selection for an off-the-shelf type KRAS cancer vaccine: epitopes of non-mutated lesion
by: Eunkyo Joung, et al.
Published: (2023-11-01)

817 AST-201 (pUMVC3-hIGFBP2 N-terminus) demonstrates anti-tumor effect in an ovarian cancer mouse model
by: Mary L Disis, et al.
Published: (2023-11-01)

Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs
by: Elena Díaz-Rodríguez, et al.
Published: (2021-12-01)

1422 Th1-specific TROP2 vaccine (AST-07X) elicits strong antigen-specific T cell responses in vitro
by: Eunkyo Joung, et al.
Published: (2023-11-01)

Therapeutic Application of Drug-Conjugated HER2 Oligobody (HER2-DOligobody)
by: Hyun Jung Kim, et al.
Published: (2020-05-01)

It's her platform
by: Lim, Teik Huat
Published: (2018)

Enhanced Immunogenicity of Engineered HER2 Antigens Potentiates Antitumor Immune Responses
by: Insu Jeon, et al.
Published: (2020-07-01)

Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors
by: Blair McNamara, et al.
Published: (2023-11-01)

Molecular Genealogy of a Mongol Queen's Family and Her Possible Kinship with Genghis Khan.
by: Gavaachimed Lkhagvasuren, et al.
Published: (2016-01-01)

Activated TAZ induces liver cancer in collaboration with EGFR/HER2 signaling pathways
by: Hyuk Moon, et al.
Published: (2022-04-01)

Her voice lingers on and her memory is strategic: effects of gender on directed forgetting.
by: Hwajin Yang, et al.
Published: (2013-01-01)

Her
by: Kim, Sung Hwan, 1975-
Published: (2012)

An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2‐Antibody‐Drug Conjugate against Refractory HER2‐Positive Cancers
by: Seol Hwa Shin, et al.
Published: (2021-12-01)

Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
by: Juin Park, et al.
Published: (2023-12-01)

Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers
by: Byoungsan Choi, et al.
Published: (2020-04-01)

Her ideal platform
by: Lim, Teik Huat
Published: (2018)

A Novel Dual-Payload ADC for the Treatment of HER2+ Breast and Colon Cancer
by: Candice Maria Mckertish, et al.
Published: (2023-07-01)

Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer
by: Joohyun Hong, et al.
Published: (2022-06-01)

PET imaging of HER2 expression with an 18F-fluoride labeled aptamer.
by: Hyun Jeong Kim, et al.
Published: (2019-01-01)

Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancer
by: Kyoungmin Lee, et al.
Published: (2023-06-01)

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
by: Laura Morsberger, et al.
Published: (2022-11-01)

Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer
by: Soohyeon Lee, et al.
Published: (2022-04-01)

Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification
by: Doo-Yi Oh, et al.
Published: (2017-08-01)

HER2 signaling regulates HER2 localization and membrane retention.
by: Jaekwang Jeong, et al.
Published: (2017-01-01)

BCL-2, HER1, HER2, HER3 and HER4 expression in primary colorectal adenocarcinoma
by: Ahmad Zubir, Nurul Mahirah
Published: (2017)

Development of HER2-Specific Aptamer-Drug Conjugate for Breast Cancer Therapy
by: Hwa Yeon Jeong, et al.
Published: (2020-12-01)

Can China Meet Her Employment Challenges?
by: Park, A, et al.
Published: (2010)

Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer
by: Yeon Hee Park, et al.
Published: (2023-07-01)

The Sayyids and the Lodis 1414-1526 [filem jalur] /
by: 230346 Williams, John Alden, et al.
Published: (1979)

Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer Patients
by: Ji Young You MD, et al.
Published: (2023-11-01)

1162 Upregulation of metabolism enzymes mediatesADC resistance in a HER2-positive cancer cell line
by: Dong Wang, et al.
Published: (2023-11-01)

Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions
by: Emanuela Ferraro, et al.
Published: (2021-08-01)

Combination of 131I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model
by: Nagarajan Vinod, et al.
Published: (2021-06-01)

143 Correlating RNA-seq detection and IHC staining of potential antibody-drug conjugate (ADC) targets: HER3, HER2, TROP2, Nectin4, and aFLR
by: Funda Meric-Bernstam, et al.
Published: (2023-11-01)

Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy.
by: James Crespo, et al.
Published: (2020-01-01)

HER2, estrogen receptor-negative metastatic hidradenocarcinoma: identification of TP53 mutation in both primary and cell-free DNA
by: Siho Kim, et al.
Published: (2017-03-01)

DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors
by: Xi Li, et al.
Published: (2024-04-01)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
by: Avisek Majumder, et al.
Published: (2021-04-01)